Ro18-5362
目录号 : GC30746
Ro18-5362是一种活性较低的Ro18-5364前体。即使在浓度高达0.1mM下，Ro18-5362也不能显着影响H++K+-ATPase活性。
Cas No.:101387-97-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ro18-5362 is the less active prodrug of Ro 18-5364. Even at concentrations as high as 0.1 mM Ro 18-5362 fails to affect significantly (H++K+)-ATPase activity and associated proton translocation.
Marked differences are seen between Ro 18-5364 (sulfoxide) and Ro18-5362 (sulfide) with regard to inhibitory activity. Even at concentrations as high as 0.1 mM Ro18-5362 fails to affect significantly (H++K+)-ATPase activity and associated proton translocation[1]. The sulfoxide Ro 18-5364, a potential metabolite of the IND Ro18-5362, is a powerful inhibitor of gastric mucosal (H++K+)-ATPase, decreasing enzymatic activity with an apparent Ki of 0.1 μM[2].
[1]. Sigrist-Nelson K, et al. Ro 18-5364, a potent new inhibitor of the gastric (H+ + K+)-ATPase. Eur J Biochem. 1987 Jul 15;166(2):453-9. [2]. Sigrist-Nelson K, et al. Gastric (H+ + K+)-ATPase: modulation of the inhibitory properties of the novel potent antisecretagogue Ro 18-5364 by sulfhydryl reagents and nucleotides. FEBS Lett. 1986 Mar 3;197(1-2):187-91.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5283 mL | 12.6416 mL | 25.2832 mL |
| 5 mM | 0.5057 mL | 2.5283 mL | 5.0566 mL |
| 10 mM | 0.2528 mL | 1.2642 mL | 2.5283 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。